Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 48
Filtrar
2.
Drug Alcohol Rev ; 37(4): 440-449, 2018 05.
Artigo em Inglês | MEDLINE | ID: mdl-29744980

RESUMO

INTRODUCTION AND AIMS: Take-home naloxone (THN) programs commenced in Australia in 2012 in the Australian Capital Territory and programs now operate in five Australian jurisdictions. The purpose of this paper is to record the progress of THN programs in Australia, to provide a resource for others wanting to start THN projects, and provide a tool for policy makers and others considering expansion of THN programs in this country and elsewhere. DESIGN AND METHODS: Key stakeholders with principal responsibility for identified THN programs operating in Australia provided descriptions of program development, implementation and characteristics. Short summaries of known THN programs from each jurisdiction are provided along with a table detailing program characteristics and outcomes. RESULTS: Data collected across current Australian THN programs suggest that to date over 2500 Australians at risk of overdose have been trained and provided naloxone. Evaluation data from four programs recorded 146 overdose reversals involving naloxone that was given by THN participants. DISCUSSION AND CONCLUSIONS: Peer drug user groups currently play a central role in the development, delivery and scale-up of THN in Australia. Health professionals who work with people who use illicit opioids are increasingly taking part as alcohol and other drug-related health agencies have recognised the opportunity for THN provision through interactions with their clients. Australia has made rapid progress in removing regulatory barriers to naloxone since the initiation of the first THN program in 2012. However, logistical and economic barriers remain and further work is needed to expand access to this life-saving medication.


Assuntos
Overdose de Drogas/tratamento farmacológico , Usuários de Drogas , Redução do Dano , Naloxona/uso terapêutico , Antagonistas de Entorpecentes/uso terapêutico , Austrália , Humanos , Desenvolvimento de Programas , Avaliação de Programas e Projetos de Saúde
3.
Drug Alcohol Rev ; 37(6): 697-720, 2018 09.
Artigo em Inglês | MEDLINE | ID: mdl-29239048

RESUMO

ISSUES: Addiction treatment providers' views about the disease model of addiction (DMA), and their contemporary views about the brain disease model of addiction (BDMA), remain an understudied area. We systematically reviewed treatment providers' attitudes about the DMA/BDMA, examined factors associated with positive or negative attitudes and assessed their views on the potential clinical impact of both models. APPROACH: Pubmed, EMBASE, PsycINFO, CINAHL Plus and Sociological Abstracts were systematically searched. Original papers on treatment providers' views about the DMA/BDMA and its clinical impact were included. Studies focussing on tobacco, behavioural addictions or non-Western populations were excluded. KEY FINDINGS: The 34 included studies were predominantly quantitative and conducted in the USA. Among mixed findings of treatment providers' support for the DMA, strong validity studies indicated treatment providers supported the disease concept and moral, free-will or social models simultaneously. Support for the DMA was positively associated with treatment providers' age, year of qualification, certification status, religious beliefs, being in recovery and Alcoholics Anonymous attendance. Greater education was negatively associated with DMA support. Treatment providers identified potential positive (e.g. reduced stigma) and negative (e.g. increased sense of helplessness) impacts of the DMA on client behaviour. IMPLICATIONS/CONCLUSION: The review suggests treatment providers may endorse disease and other models while strategically deploying the DMA for presumed therapeutic benefits. Varying DMA support across workforces indicated service users may experience multiple and potentially contradictory explanations of addiction. Future policy development will benefit by considering how treatment providers adopt disease concepts in practice.


Assuntos
Atitude do Pessoal de Saúde , Comportamento Aditivo/terapia , Conhecimentos, Atitudes e Prática em Saúde , Modelos Teóricos , Transtornos Relacionados ao Uso de Substâncias/terapia , Humanos
5.
Int J Drug Policy ; 36: 47-57, 2016 10.
Artigo em Inglês | MEDLINE | ID: mdl-27455467

RESUMO

BACKGROUND: Smartphone technologies and mHealth applications (or apps) promise unprecedented scope for data collection, treatment intervention, and relapse prevention when used in the field of substance abuse and addiction. This potential also raises new ethical challenges that researchers, clinicians, and software developers must address. AIMS: This paper aims to identify ethical issues in the current uses of smartphones in addiction research and treatment. METHODS: A search of three databases (PubMed, Web of Science and PsycInfo) identified 33 studies involving smartphones or mHealth applications for use in the research and treatment of substance abuse and addiction. A content analysis was conducted to identify how smartphones are being used in these fields and to highlight the ethical issues raised by these studies. RESULTS: Smartphones are being used to collect large amounts of sensitive information, including personal information, geo-location, physiological activity, self-reports of mood and cravings, and the consumption of illicit drugs, alcohol and nicotine. Given that detailed information is being collected about potentially illegal behaviour, we identified the following ethical considerations: protecting user privacy, maximising equity in access, ensuring informed consent, providing participants with adequate clinical resources, communicating clinically relevant results to individuals, and the urgent need to demonstrate evidence of safety and efficacy of the technologies. CONCLUSIONS: mHealth technology offers the possibility to collect large amounts of valuable personal information that may enhance research and treatment of substance abuse and addiction. To realise this potential researchers, clinicians and app-developers must address these ethical concerns to maximise the benefits and minimise risks of harm to users.


Assuntos
Pesquisa Biomédica/ética , Confidencialidade/ética , Aplicativos Móveis/ética , Smartphone/ética , Transtornos Relacionados ao Uso de Substâncias/terapia , Telemedicina/ética , Comportamento Aditivo , Pesquisa Biomédica/instrumentação , Pesquisa Biomédica/tendências , Confidencialidade/tendências , Anonimização de Dados/ética , Difusão de Inovações , Previsões , Humanos , Armazenamento e Recuperação da Informação/ética , Aplicativos Móveis/tendências , Smartphone/tendências , Transtornos Relacionados ao Uso de Substâncias/diagnóstico , Transtornos Relacionados ao Uso de Substâncias/psicologia , Telemedicina/instrumentação , Telemedicina/tendências , Consentimento do Representante Legal/ética , Resultado do Tratamento
7.
New Bioeth ; 21(2): 128-41, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-27124961

RESUMO

The concepts of 'biopolitics' and 'naked life' have become increasingly relevant in the debate on substance dependency due to the growing prominence of neuroscience in defining the nature of addiction and its threat to agency. However, these concepts are not necessarily well understood, and therefore may lead to oversight rather than insight. In this article we review the literature on Italian philosopher Giorgio Agamben, whose founding works on both concepts shed a different light on addiction. We argue that the current debate is missing a key insight from Agamben's work: the idea of agency past the subject, of agency past identity. We will illustrate how this can be an important form of agency against the stigmatization of users, making use of empirical data from our ongoing work on addiction and agency.


Assuntos
Comportamento Aditivo , Temas Bioéticos , Usuários de Drogas , Autonomia Pessoal , Estigma Social , Transtornos Relacionados ao Uso de Substâncias , Humanos , Pesquisa Qualitativa
8.
Acad Emerg Med ; 21(11): 1226-31, 2014 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-25377399

RESUMO

OBJECTIVES: The objective was to examine the effect of endotracheal intubation on emergency department (ED) length of stay (LOS) and admission rates for patients with gamma-hydroxybutyrate (GHB) overdose. METHODS: A 3-year retrospective electronic and paper audit of recreational drug presentations was carried out at two major inner-city EDs in Melbourne, Australia. Different GHB overdose management strategies exist at the respective audit sites, namely: 1) all patients with a Glasgow Coma Scale (GCS) score of 8 or less are intubated or 2) uncomplicated patients with GCS scores of 8 or less are managed without intubation (conservative management), unless further complications arise. This difference allows for comparison of the effects of intubation. All suspected GHB-related cases (defined as cases where GHB or its analogs gamma-butyrolactone or 1,4-butanediol were recorded) in which altered consciousness state was noted as a presenting symptom at triage were selected from all recreational drug-related presentations occurring between January 2008 and December 2010. The relationship between intubation and the primary outcome, ED LOS, was examined using robust regression after adjustment for potential confounders. The relationship between intubation and admission status (admission to hospital versus discharge) was also examined using logistic regression. RESULTS: After adjustment for potential confounders such as GCS score, intubation of GHB-related cases in the ED was associated with an increase in mean LOS of 41% (95% confidence interval [CI] = 19% to 65%) and an increase in the odds of admission to hospital of 9.95 (95% CI = 2.36 to 41.88) at one hospital site, compared to conservative airway management. CONCLUSIONS: Conservative airway management (no intubation) is associated with shorter ED LOS in cases of uncomplicated GHB-related coma in the ED and may also be associated with lower admission rates for these patients.


Assuntos
Overdose de Drogas/terapia , Serviço Hospitalar de Emergência , Intubação Intratraqueal/métodos , Tempo de Internação/tendências , Oxibato de Sódio/efeitos adversos , Adulto , Anestésicos Intravenosos/efeitos adversos , Feminino , Seguimentos , Escala de Coma de Glasgow , Humanos , Masculino , Estudos Retrospectivos , Oxibato de Sódio/administração & dosagem , Resultado do Tratamento , Adulto Jovem
9.
Emerg Med J ; 31(4): 317-22, 2014 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-23404807

RESUMO

OBJECTIVE: To describe patterns and characteristics of emergency department (ED) presentations related to the use of ecstasy and related drugs (ERDs) in Melbourne, Australia. METHODS: Retrospective audit of ERD-related presentations from 1 January 2008 to 31 December 2010 at two tertiary hospital EDs. Variation in presentations across years was tested using a two-tailed test for proportions. Univariate and multivariate logistic regressions were used to compare sociodemographic and clinical characteristics across groups. RESULTS: Most of the 1347 presentations occurred on weekends, 24:00-06:00. Most patients arrived by ambulance (69%) from public places (42%), private residences (26%) and licensed venues (21%). Ecstasy-related presentations decreased from 26% of presentations in 2008 to 14% in 2009 (p<0.05); γ-hydroxybutyrate (GHB) presentations were most common overall. GHB presentations were commonly related to altered conscious state (89%); other presentations were due to psychological concerns or nausea/vomiting. Compared with GHB presentations, patients in ecstasy-related presentations were significantly less likely to require intubation (OR 0.04, 95% CI 0.01 to 0.18), but more likely to result in hospital admission (OR 1.77, 95% CI 1.08 to 2.91). Patients in amphetamine-related cases were older than those in GHB-related cases (median 28.4 years vs 23.9 years; p<0.05), and more likely to have a history of substance use (OR 4.85, 95% CI 3.50 to 6.74) or psychiatric illness (OR 6.64, 95% CI 4.47 to 9.87). Overall, the median length of stay was 3.0 h (IQR 1.8-4.8), with most (81%) patients discharged directly home. CONCLUSIONS: Although the majority of ERD-related presentations were effectively treated, with discharge within a short time frame, the number and timing of presentations places a significant burden on EDs. ERD harm reduction and improved management of minor harms at licensed venues could reduce this burden.


Assuntos
Transtornos Relacionados ao Uso de Anfetaminas/epidemiologia , Serviço Hospitalar de Emergência/estatística & dados numéricos , Adulto , Auditoria Clínica , Feminino , Alucinógenos/efeitos adversos , Hospitais Urbanos/estatística & dados numéricos , Humanos , Modelos Logísticos , Masculino , N-Metil-3,4-Metilenodioxianfetamina/efeitos adversos , Análise de Regressão , Estudos Retrospectivos , Fatores Socioeconômicos , Austrália do Sul/epidemiologia , Adulto Jovem
11.
N S W Public Health Bull ; 23(5-6): 116-9, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22738622

RESUMO

Beyond the usual technical and evidentiary considerations, there are ethical questions that we must consider in the justification of our obesity interventions in the name of expected population health gains. These relate to the types of health identities that are permitted in society, the possible unintended consequences of preferencing certain health identities over others, and the manner in which public health policies and interventions are justified. The prevalence of overweight and obesity in Australia highlights some of the areas of uncertainty and identifies some important ethical questions that arise as a result of this uncertainty. I propose that the Australian obesity prevention strategy could be evaluated using the Nuffield Council on Bioethics stewardship model of public health to assess whether any current approaches exceed recommended intervention constraints or limits. My aim is to prompt further debate on this topic.


Assuntos
Política de Saúde , Obesidade , Saúde Pública/ética , Austrália/epidemiologia , Bioética , Programas Governamentais/ética , Humanos , Obesidade/epidemiologia , Obesidade/prevenção & controle , Sobrepeso/epidemiologia , Sobrepeso/prevenção & controle
12.
J Med Ethics ; 38(9): 535-9, 2012 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-22573881

RESUMO

National electronic health record initiatives are in progress in many countries around the world but the debate about the ethical issues and how they are to be addressed remains overshadowed by other issues. The discourse to which all others are answerable is a technical discourse, even where matters of privacy and consent are concerned. Yet a focus on technical issues and a failure to think about ethics are cited as factors in the failure of the UK health record system. In this paper, while the prime concern is the Australian Personally Controlled Electronic Health Record (PCEHR), the discussion is relevant to and informed by the international context. The authors draw attention to ethical and conceptual issues that have implications for the success or failure of electronic health records systems. Important ethical issues to consider as Australia moves towards a PCEHR system include: issues of equity that arise in the context of personal control, who benefits and who should pay, what are the legitimate uses of PCEHRs, and how we should implement privacy. The authors identify specific questions that need addressing.


Assuntos
Registros Eletrônicos de Saúde/ética , Programas Nacionais de Saúde/ética , Acesso à Informação , Atitude Frente aos Computadores , Austrália , Segurança Computacional/ética , Confidencialidade/ética , Registros Eletrônicos de Saúde/legislação & jurisprudência , Conhecimentos, Atitudes e Prática em Saúde , Política de Saúde/legislação & jurisprudência , Humanos , Programas Nacionais de Saúde/legislação & jurisprudência , Guias de Prática Clínica como Assunto , Reino Unido
14.
Health Promot J Austr ; 21(3): 170-5, 2010 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-21118062

RESUMO

The national health reform reviews conducted recently in Australia ('Henry Review', National Preventative Health Taskforce, National Health and Hospitals Reform Commission) have seen significant energy invested in articulating a new vision for health promotion and disease prevention in this country. This is an opportune time to think critically about the underpinning frameworks that we want to guide our decisions and actions in public health policy, practice and research. The purpose of this piece is to raise questions for debate in relation to the issues of competing professional interests and perspectives, intervention limits, permissible health identities; and what these might mean for the justification of health promotion and prevention interventions in a changing funding and policy environment.


Assuntos
Promoção da Saúde/organização & administração , Prevenção Primária/organização & administração , Austrália , Comportamento Cooperativo , Política de Saúde , Promoção da Saúde/legislação & jurisprudência , Humanos , Política , Prevenção Primária/ética , Prevenção Primária/legislação & jurisprudência , Prática de Saúde Pública
17.
Subst Use Misuse ; 45(3): 437-50, 2010 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-20141457

RESUMO

The usage of Ecstasy and related drug (ERD) has increasingly been the focus of epidemiological and other public health-related research. One of the more promising methods is the use of the Internet as a recruitment and survey tool. However, there remain methodological concerns and questions about representativeness. Three samples of ERD users in Melbourne, Australia surveyed in 2004 are compared in terms of a number of key demographic and drug use variables. The Internet, face-to-face, and probability sampling methods appear to access similar but not identical groups of ERD users. Implications and limitations of the study are noted and future research is recommended.


Assuntos
Usuários de Drogas/estatística & dados numéricos , Métodos Epidemiológicos , Inquéritos Epidemiológicos , Internet , Transtornos Relacionados ao Uso de Substâncias/epidemiologia , Adolescente , Adulto , Feminino , Humanos , Drogas Ilícitas , Masculino , Pessoa de Meia-Idade , N-Metil-3,4-Metilenodioxianfetamina/administração & dosagem , Estudos de Amostragem
18.
Subst Use Misuse ; 45(1-2): 266-87, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-20025453

RESUMO

There is increasing pressure on drug monitoring systems to achieve earlier detection and greater precision in reporting of emerging drug use trends. Such systems typically operate in settings where government interest and the drug use trends themselves can be fluid. To achieve the goal of informing timely policy and practice responses in this environment, drug use monitoring systems must be flexible and responsive, as well as reliable and valid. This paper explores three interrelated areas relevant to trend monitoring that can benefit from a clearer focus in terms of increasing validity and reliability: the research paradigm to which systems adhere; the selection of sources or drug use indicators utilized by systems; and the process of analysis used by systems to ensure valid results. The reliability and validity of currently utilized drug use related indicators is discussed, with a focus on the validity of data sources as measures of emerging drug use trends. The relevance and utility of current descriptives such as "lagged" and "leading edge" indicators are assessed. Five dimensions, against which the validity of drug use indicators may be assessed in a trend-monitoring context are proposed as an alternative. Faced with a lack of clear conceptual frameworks underpinning and driving monitoring systems, it is argued that a pragmatic research paradigm can be adopted as a basis for guiding selection of indicators and helping to make explicit the concurrent or supplementary triangulation and analysis procedures on which valid results are necessarily founded. The current trend of using triangulation as the primary means of ensuring the validity of systems is critically reviewed and a challenge is issued to the field to make the analysis process more overt. No external funding was received for this article.


Assuntos
Coleta de Dados/métodos , Serviços de Informação sobre Medicamentos/normas , Detecção do Abuso de Substâncias/métodos , Transtornos Relacionados ao Uso de Substâncias/epidemiologia , Humanos , Reprodutibilidade dos Testes
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...